ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.

The usefulness of serum pro-gastrin-releasing peptide (ProGRP) as a tumor marker in patients with small cell lung cancer has recently drawn the attention of many research centers. The aim of the study was the evaluation of ProGRP, neuron-specific enolase (NSE), soluble fragment of cytokeratin 19 (CYFRA 21-1) and lactate dehydrogenase (LDH) levels at the time of diagnosis and during chemo- and radiotherapy of small cell lung cancer patients with limited disease (SCLC-LD). The studies were performed on a group of 64 patients with SCLC-LD who had received no prior therapy. All the patients were given the same treatment regimen. ProGRP, NSE, CYFRA 21-1 and LDH were measured before each course of chemotherapy and then at 3 and 6 months after the end of treatment. Prior to therapy, elevated levels of ProGRP, NSE, CYFRA 21-1 and LDH were found in 79.7%, 57.8%, 23.4%, and 12.5% of the patients respectively. Before the second chemotherapy course, all the tumor marker levels except LDH decreased significantly in comparison with the pretreatment concentrations. However, only ProGRP levels showed a progressive drop during consecutive courses of therapy, while NSE and CYFRA 21-1 fluctuated within reference ranges. When the study group was divided with respect to the effect of treatment evaluated six months from its termination, significant differences in ProGRP levels were found between both subgroups throughout all therapy and follow-up, except for the fifth course of chemotherapy. Differences in NSE levels were only significant for the first two courses and follow-up. Univariate analysis showed significant relationships between disease-free survival and the initial levels of NSE and CYFRA 21-1 as well as between overall survival and prophylactic cranial irradiation (PCI) and the initial ProGRP, NSE and CYFRA 21-1 levels. Changes of ProGRP level seem to be more precise than NSE as a tool for monitoring therapy in SCLC patients with limited disease, but for prediction of relapse, in addition to NSE determinations of ProGRP seem to be optimal.

[1]  G. Oremek,et al.  Value of tumour and inflammatory markers in lung cancer. , 2007, Anticancer research.

[2]  O. Nilsson,et al.  Production and Characterization of Monoclonal Antibodies for Immunoassay of the Lung Cancer Marker proGRP , 2007, Tumor Biology.

[3]  N. Viñolas,et al.  Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. , 2005, Anticancer research.

[4]  N. Viñolas,et al.  Pro-Gastrin-Releasing Peptide in Patients with Benign and Malignant Diseases , 2004, Tumor Biology.

[5]  Makoto Suzuki,et al.  The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. , 2004, Anticancer research.

[6]  P. Lamy,et al.  Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. , 2003, Lung cancer.

[7]  J. Schneider,et al.  Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer. , 2003, Clinical laboratory.

[8]  J. Kulpa,et al.  Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. , 2002, Clinical chemistry.

[9]  K. Kiura,et al.  Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). , 2001, Lung cancer.

[10]  P. Lamy,et al.  Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. , 2000, Lung cancer.

[11]  H. Ohmatsu,et al.  Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. , 2000, Lung cancer.

[12]  H. Dienemann,et al.  Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas. , 1999, Anticancer research.

[13]  R. Arriagada,et al.  Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy , 1998, Cancer.

[14]  K. Eguchi,et al.  Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  P. Johnson,et al.  Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. , 1996, British Journal of Cancer.

[16]  M. Fukuoka,et al.  Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. , 1996, British Journal of Cancer.

[17]  N. Maki,et al.  Enzyme‐linked Immunosorbent Assay of Pro‐gastrin‐releasing Peptide for Small Cell Lung Cancer Patients in Comparison with Neuron‐specific Enolase Measurement , 1995, Japanese journal of cancer research : Gann.

[18]  K. Aoyagi,et al.  Enzyme immunoassay of immunoreactive progastrin-releasing peptide(31-98) as tumor marker for small-cell lung carcinoma: development and evaluation. , 1995, Clinical chemistry.

[19]  K. Yamaguchi,et al.  Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. , 1994, Cancer research.

[20]  M. Pandian,et al.  Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. , 1993, British Journal of Cancer.

[21]  S. Kaye,et al.  Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance? , 1990, British Journal of Cancer.

[22]  H. Hansen,et al.  Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. , 1989, European journal of cancer & clinical oncology.

[23]  J. Battey,et al.  Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer: a novel peptide family found in man. , 1988, The Journal of clinical endocrinology and metabolism.

[24]  D. Carney,et al.  Neuron-specific enolase: how useful as a cancer marker? , 1988, European journal of cancer & clinical oncology.

[25]  N. Vogelzang,et al.  Tumor lysis syndrome after induction chemotherapy of small-cell bronchogenic carcinoma. , 1983, JAMA.

[26]  J. Minna,et al.  SERUM NEURON-SPECIFIC ENOLASE: A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCER , 1982, The Lancet.